Phase 1 study of LL10 (QX-OH 1.26%/levobupivacaine 0.325%) in 137 healthy volunteers: no severe adverse events; femoral nerve block lasted longer than levobupivacaine (median 25.0 vs 15.5 h) but not s.c. infiltration or TAP block.
RCTn = 137
Fang et al. Phase 1 single-centre, placebo and levobupivacaine controlled study in healthy volunteers to assess the safety, tolerability, efficacy, and pharmacokinetics of LL10, a novel long-acting local anaesthetic